Survival analysis of presumptive prognostic markers among oligodendrogliomas

Cancer

Volumn 104, Issue 8, 2005, Pages 1693-1699

  McLendon, Roger E ^a   Herndon II, James E ^a   West, Bryan ^a   Reardon, David ^a   Wiltshire, Rodney ^a,b   Rasheed, B K Ahmed ^a   Quinn, Jennifer ^a   Friedman, Henry S ^a   Friedman, Allan H ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

19q; 1p; 9p21; Fluorescence in situ hybridization; Genetic testing; Methylguanine methyltransferase; Oligodendroglioma; TP53

Indexed keywords

METHYLGUANINE METHYLTRANSFERASE; METHYLTRANSFERASE; PROTEIN P53; UNCLASSIFIED DRUG;

ALLELISM; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 9P; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA REPAIR; FOLLOW UP; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

BRAIN NEOPLASMS; CHROMOSOMES, HUMAN; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; IN SITU HYBRIDIZATION; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 26444453809     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21362     Document Type: Article

References (26)

1. Jeuken JW, Sprenger SH, Wesseling P, et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol. 1999;58:606-612.
2. Burger PC, Minn AY, Smith JS, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol. 2001;14:842-853.
3. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (Berl). 2002;103:267-275.
4. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-845.
5. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56:1098-1104.
6. McLendon RE, Rasheed A, Wiltshire R, Herndon J. Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma. Mod Pathol. 2004;17:604-605.
7. Rasheed A, Herndon JE, Stenzel TT, et al. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002;94:2688-2697.
8. Wiltshire RN, Herndon JE, Lloyd A, et al. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. J Mol Diagn. 2004;6:166-179.
9. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol. 2002;61:58-63.
10. Nutt CL, Noble M, Chambers AF, Cairncross JG. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res. 2000;60:4812-4818.
11. Branle F, Lefranc F, Camby I, et al. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer. 2002;95:641-655.
12. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-386.
13. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857.
14. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175-1190.
15. Hartmann C, Johnk L, Kitange G, et al. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res. 2002;62:4100-4108.
16. Burton EC, Lamborn KR, Feuerstein BG, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res. 2002;62:6205-6210.
17. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol. 2003;10:212-217.
18. Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997;3:837-847.
19. Kornberg A, Baker T. DNA replication. 2nd ed. New York: W. H. Freeman, 1992.
20. Ostrowski LE, von Wronski MA, Bigner SH, et al. Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines. Carcinogenesis. 1991;12:1739-1744.
21. Nakasu S, Fukami T, Baba K, Matsuda M. Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol. 2004;70:333-340.
22. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bischloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998;16:3310-3315.
23. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
24. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2005;113:379-385.
25. LeDoux SP, Williams BA, Hollensworth BS, et al. Glial cell-specific differences in repair of O6-methylguanine. Cancer Res. 1996;56:5615-5619.
26. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol. 2003;62:111-126.